Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936496 | 0.72 | — | — | |
| SCHEMBL3941115 | 0.70 | MAPK1 (0.30) | — | |
| SCHEMBL82882 | 0.68 | EGFR (0.37) | ALDH1A1MAPTEGFRSMN1; SMN2 | |
| SCHEMBL3940440 | 0.68 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTPDK1LMNA | |
| SCHEMBL3933699 | 0.67 | EGFR (0.35) | EGFR | |
| SCHEMBL10851 | 0.67 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTPDK1GMNN | |
| SCHEMBL276596 | 0.67 | KDM4E (0.41) | ALDH1A1KDM4EMAPTGMNNLMNA | |
| SCHEMBL4421566 | 0.66 | NPC1 (0.43) | ALDH1A1KDM4EMAPTEGFRLMNA | |
| SCHEMBL8778 | 0.65 | LMNA (0.31) | KDM4EMAPTGMNNLMNATP53 | |
| SCHEMBL3938300 | 0.65 | ALDH1A1 (0.38) | ALDH1A1KDM4EMAPTPDK1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | claimed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | claimed |
| US-20230149409-A1 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | INCYTE CORPORATION | 2023-05-18 | — | — | US | claimed |
| US-20230117605-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2023-04-20 | — | — | US | claimed |
| WO-2023049831-A1 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | INCYTE CORPORATION (US) | 2023-03-30 | — | — | WO | claimed |
| EP-4146264-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | claimed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | claimed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | claimed |
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-09-11 | — | — | US | claimed |
| EP-2766358-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-08-20 | — | — | EP | claimed |
| WO-2014120658-A1 | FUSED MULTICYCLIC 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE DERIVATIVES AND THEIR USE AS BETA-SECRETASE INHIBITORS | AMGEN INC. (US) | 2014-08-07 | — | — | WO | claimed |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC. | 2014-07-31 | — | — | US | claimed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | claimed |
| WO-2013054291-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-04-18 | — | — | WO | claimed |
| US-6784174-B1 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TNF | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | claimed |
| EP-1165566-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117605-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | ALDH1A1 3476/4885KDM4E 3281/4885MAPT 3696/4885 |
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | BACE2, BACE1, PSEN1 | ALDH1A1 252/4885KDM4E 3301/4885MAPT 46/4885 |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | ALDH1A1 2893/4885KDM4E 3196/4885MAPT 3982/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | ALDH1A1 2861/4885KDM4E 2899/4885MAPT 4023/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | ALDH1A1 3323/4885KDM4E 4191/4885MAPT 4071/4885 |
| US-20140213581-A1 | FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | ALDH1A1 2127/4885KDM4E 2858/4885MAPT 737/4885 |
| US-20230149409-A1 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | PDCD1LG2, CD274, PDCD1 | ALDH1A1 856/4885KDM4E 1249/4885MAPT 3237/4885 |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | ALDH1A1 4093/4885KDM4E 1599/4885MAPT 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.